Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Thromb Thrombolysis ; 44(4): 466-474, 2017 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-28994036

RESUMO

Aim of the study was to compare four different strategies of dual antiplatelet therapy (DAPT) in patients with acute coronary syndromes (ACS) treated with PCI. DAPT with Clopidogrel, Ticagrelor and Prasugrel has proved to be effective in patients with ACS treated with percutaneous coronary intervention (PCI) by reducing major adverse cardiovascular outcomes (MACE). However, the effect of the different strategies in a real-world population deserves further verification. A retrospective analysis of 2404 discharged ACS patients treated with PCI was performed, with a median follow-up of 1 year. The study population was stratified in four drug treatment cohorts: ASA + Clopidogrel (A-C), ASA + Plavix (A-PLx), ASA + Ticagrelor (A-T), ASA + Prasugrel (A-P). We assessed the incidence of net adverse cardiovascular events (NACE): all-cause death, myocardial infarction (MI), target vessel revascularization (TVR), stroke and bleeding during follow-up. At 1-year, the use of A-C and A-PLx was associated with the highest cumulative incidence of NACE in comparison with A-T and A-P therapies (respectively 14.8 and 29.6% vs. 9.2 and 6%). This difference was mainly driven by the mortality and TVR outcomes. Considering selection bias and differences in the patients baseline characteristics, the association of A-T and A-P seems to be superior in comparison with a DAPT strategy of A-C and A-PLx in low risk ACS-PCI patients from real world. In our Region the prescription is consistent with guidelines recommendations and Clopidogrel and Plavix are still predominantly used in older patients with more comorbidities, and this could partially explain the inferiority of this association.


Assuntos
Síndrome Coronariana Aguda/terapia , Intervenção Coronária Percutânea , Inibidores da Agregação Plaquetária/administração & dosagem , Síndrome Coronariana Aguda/tratamento farmacológico , Síndrome Coronariana Aguda/cirurgia , Adenosina/análogos & derivados , Adenosina/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Clopidogrel , Feminino , Humanos , Itália , Masculino , Pessoa de Meia-Idade , Inibidores da Agregação Plaquetária/uso terapêutico , Cuidados Pós-Operatórios , Cloridrato de Prasugrel/uso terapêutico , Sistema de Registros , Estudos Retrospectivos , Ticagrelor , Ticlopidina/análogos & derivados , Ticlopidina/uso terapêutico
2.
J Inorg Biochem ; 99(3): 822-7, 2005 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-15708804

RESUMO

Aluminium (Al (III)) is a metal with no biological function. Its organic accumulation can lead to toxic effects. To elucidate the in vivo effect of Al (III) upon the rheological properties of the erythrocyte membrane, male adult Wistar rats have been submitted to periodical injections of Al(OH)3 during three months. Significant decreases in haematocrit (34+/-0.37% versus 36+/-0.20%, p<0.0001) and blood haemoglobin concentration (10.7+/-0.15 g/dl versus 12.3+/-0.49 g/dl, p<0.005) have been found. Haemolysis curves shifted towards the left, indicating that erythrocytes became more resistant to hypotonic haemolysis. Significant increments in rigidity index (29.6+/-1.59 versus 9.2+/-0.40, p<0.0001), relative viscosity at native haematocrit (3.6+/-0.03 versus 3.5+/-0.03, p<0.04), and relative viscosity at standard haematocrit (4.5+/-0.06 versus 3.9+/-0.05, p<0.0001) have been observed. The decrease in the erythrocyte aggregate size (1.6+/-0.01 versus 1.7+/-0.01, p<0.002) and the aggregation rate (0.5+/-0.02 versus 0.6+/-0.03, p<0.002) indicated a significantly dropped aggregability process. In conclusion, Al (III) disorganised the erythrocyte membrane by altering its mechanical properties, suggesting a reduction of the middle life of circulating erythrocytes, which could play a major role in the anaemia of these animals.


Assuntos
Alumínio/farmacologia , Deformação Eritrocítica/efeitos dos fármacos , Membrana Eritrocítica/efeitos dos fármacos , Alumínio/toxicidade , Anemia Hemolítica Autoimune/sangue , Animais , Viscosidade Sanguínea , Cátions , Agregação Eritrocítica/efeitos dos fármacos , Membrana Eritrocítica/química , Hematócrito , Hemoglobinas/metabolismo , Hemólise/efeitos dos fármacos , Hemólise/fisiologia , Cinética , Ratos
3.
Clin Hemorheol Microcirc ; 31(2): 81-7, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15310942

RESUMO

Few studies have been performed in humans to investigate the effect of caloric restriction and consequent biomass reduction on hemorheologic parameters and their results are not concurrent. In a previous paper we analyzed the rheological behavior of the blood in the IIMb/Fmbeta inbred obese and hypertriglyceridemic strain in relation to its eumetabolic control [G.N. Hernández, C. Dabin, M.C. Gayol and M.L. Rasia, Hemorheological variables in a rat model of hypertriglyceridemic obesity and diabetes, Veterinary Res. Commun. 26 (2002), 625-635]. In this obese line it was shown a higher blood and plasma viscosity and an impaired red cell deformability compared to the eumetabolic one. The increased plasma viscosity was significantly and positively associated with fibrinogenaemia and lipidaemia and the impaired erythrocyte deformability with cholesterolemia and hypertriglyceridaemia. The present study has been designed to find out the effect of a 30% food restriction on several biochemical and hemorheological parameters of these obese rats. Restriction resulted in a mean body weight 45% lower than ad libitum controls, preventing obesity and hypertriglyceridemia with minimal effect on glucose metabolism. Regarding hemorheological parameters, caloric restriction led to a decrease in blood viscosity, due to the reduction in erythrocyte concentration, but not because of any improvement in erythrocyte deformability.


Assuntos
Viscosidade Sanguínea , Diabetes Mellitus Tipo 2/sangue , Dieta Redutora , Privação de Alimentos , Hemorreologia , Hipertrigliceridemia/sangue , Obesidade/sangue , Animais , Glicemia/análise , Colesterol/sangue , Diabetes Mellitus Tipo 2/dietoterapia , Diabetes Mellitus Tipo 2/genética , Ingestão de Energia , Teste de Tolerância a Glucose , Hipertrigliceridemia/dietoterapia , Hipertrigliceridemia/genética , Masculino , Obesidade/dietoterapia , Obesidade/genética , Ratos , Ratos Endogâmicos , Ratos Mutantes , Triglicerídeos/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...